Eugene Bauer - Nov 9, 2021 Form 4 Insider Report for Kadmon Holdings, Inc. (KDMN)

Role
Director
Signature
/s/ Gregory S. Moss, Attorney-in-Fact
Stock symbol
KDMN
Transactions as of
Nov 9, 2021
Transactions value $
-$2,092,309
Form type
4
Date filed
11/9/2021, 04:35 PM
Previous filing
May 13, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KDMN Common Stock Disposed to Issuer -$16.3K -1.72K -100% $9.50 0 Nov 9, 2021 Direct F1
transaction KDMN Common Stock Disposed to Issuer -$47.5K -5K -100% $9.50 0 Nov 9, 2021 Bauer Family 1995 Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KDMN Stock Option (right to buy) Disposed to Issuer -$14.9K -3.08K -100% $4.84 0 Nov 9, 2021 Common Stock, par value $0.001 3.08K $4.66 Direct F2, F3
transaction KDMN Stock Option (right to buy) Disposed to Issuer -$135K -25K -100% $5.38 0 Nov 9, 2021 Common Stock, par value $0.001 25K $4.12 Direct F2, F3
transaction KDMN Stock Option (right to buy) Disposed to Issuer -$154K -25K -100% $6.15 0 Nov 9, 2021 Common Stock, par value $0.001 25K $3.35 Direct F2, F3
transaction KDMN Stock Option (right to buy) Disposed to Issuer -$721K -100K -100% $7.21 0 Nov 9, 2021 Common Stock, par value $0.001 100K $2.29 Direct F2, F3
transaction KDMN Stock Option (right to buy) Disposed to Issuer -$430K -85K -100% $5.06 0 Nov 9, 2021 Common Stock, par value $0.001 85K $4.44 Direct F2, F3
transaction KDMN Stock Option (right to buy) Disposed to Issuer -$574K -97K -100% $5.92 0 Nov 9, 2021 Common Stock, par value $0.001 97K $3.58 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Eugene Bauer is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Disposed pursuant to the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger (the "Merger").
F2 In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option.
F3 Represents the payment per share of Common Stock received in exchange for the cancellation of each Option.